Skip to Content

Vimizim Side Effects

Generic Name: elosulfase alfa

Note: This page contains side effects data for the generic drug elosulfase alfa. It is possible that some of the dosage forms included below may not apply to the brand name Vimizim.

In Summary

Common side effects of Vimizim include: anaphylaxis, abdominal pain, fever, hypersensitivity reaction, nausea, and vomiting. Other side effects include: cyanosis, chest discomfort, constriction of the pharynx, cough, dyspnea, gastrointestinal symptoms, hypotension, retching, skin rash, urticaria, erythema, and flushing. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to elosulfase alfa: intravenous solution

As well as its needed effects, elosulfase alfa (the active ingredient contained in Vimizim) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking elosulfase alfa, check with your doctor or nurse immediately:

More common:
  • Chills
  • cough
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • fever
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • skin rash, hives, or itching
  • tightness in the chest
  • unusual tiredness or weakness

Minor Side Effects

Some elosulfase alfa side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common:
  • Abdominal or stomach pain
  • headache
  • vomiting

For Healthcare Professionals

Applies to elosulfase alfa: intravenous solution


All patients tested positive at least once during the trial for neutralizing antibodies capable of inhibiting the drug from binding to the mannose-6-phosphate receptor; this receptor binding is needed for drug intake into cells.[Ref]

Very common (10% or more): Development of anti-drug antibodies (100%), tested positive for neutralizing antibodies (100%)[Ref]


Very common (10% or more): Pyrexia (33%), chills (10.3%), fatigue (10.3%)[Ref]


Very common (10% or more): Vomiting (31%), nausea (24%), abdominal pain (21%)[Ref]

Nervous system

Very common (10% or more): Headache (26%)[Ref]


Very common (10% or more): Hypersensitivity reactions (including anaphylaxis; 18.7%)
Common (1% to 10%): Anaphylaxis[Ref]


1. "Product Information. Vimizim (elosulfase alfa)." BioMarin Pharmaceutical Inc, Novato, CA.

It is possible that some side effects of Vimizim may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.